Research peptides and approved medicines: what is the difference?

Begin with the exact product

Separate the molecule’s name, a trial’s investigational treatment and the product listed by a retailer. Similar names do not establish that the materials are equivalent. An approval belongs to a specific medicine and its authorised conditions; it is not a general endorsement of every product using a molecule name.

A trial result answers a defined question

Read the participants, comparator, duration and outcomes. A trial result describes that study. For example, a result from a combination should not automatically be assigned to either component alone. Follow the molecule profiles for sources and keep comparisons between separate studies contextual.

An application is a step, not a decision

An application for marketing authorisation is evaluated before a decision. For centrally authorised EU medicines, EMA performs the scientific evaluation and the European Commission decides on the authorisation. Clinical trial authorisation is a separate process involving national authorities.

Read the authorised information

Use the regulator’s product information to check the medicine, indications and conditions of use. EMA’s medicine pages are useful starting points for centrally authorised products; absence from one database alone is not a complete assessment of all national authorisations.

Keep catalogue documents in their own category

A supplier COA can describe analytical results; it does not replace a medicine’s regulatory assessment. PeptideAtlas keeps science, regulatory sources and merchant information distinguishable. These guides provide no dosing, preparation or individual treatment instructions.

Primary sources

• EMA: authorisation of medicines
• EMA: marketing authorisation